Skip to main content
. 2009 Jul 7;157(8):1523–1530. doi: 10.1111/j.1476-5381.2009.00340.x

Figure 5.

Figure 5

Inhibition of nitrite vasorelaxation in endothelium-intact vessels. Inhibitor concentrations used 1H [1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) (10 µM), carboxy-2-phenyl-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide (CPTIO) (1 mM), raloxifene (50 nM), oxypurinol (100 µM), PGI2 synthase inhibitor (10 µM), l-NG-monomethyl arginine (l-NMMA) (300 µM) (n= 4 or 5). Differences between means: ODQ versus CPTIO + ODQ (not significant), CPTIO versus CPTIO + ODQ (not significant). CPTIO versus indomethacin (not significant), CPTIO versus CPTIO + indomethacin (P < 0.0001), indomethacin versus CPTIO + indomethacin (P < 0.0001). Raloxifene versus oxypurinol (P < 0.0008), raloxifene versus l-NMMA (P < 0.0003). CPTIO + indomethacin versus CPTIO + ODQ (P= 0.0705).